%D8%A7%D9%84%D8%AA%D9%87%D8%A7%D8%A8_%D8%B4%D8%A8%D9%83%D9%8A%D8%A9_%D8%A7%D9%84%D8%B9%D9%8A%D9%86RetinitisRetinitisRetinitisRetinitisRetinite%D0%A0%D0%B5%D1%82%D0%B8%D0%BD%D0%B8%D1%82Retinite%D0%A0%D0%B5%D1%82%D0%B8%D0%BD%D0%B8%D1%82%E0%AE%B5%E0%AE%BF%E0%AE%B4%E0%AE%BF%E0%AE%A4%E0%AF%8D%E0%AE%A4%E0%AE%BF%E0%AE%B0%E0%AF%88%E0%AE%AF%E0%AE%B4%E0%AE%B1%E0%AF%8D%E0%AE%9A%E0%AE%BFQ630552
about
Safety and Tolerability of hRPC in Retinitis PigmentosaIRIS PILOT - Extended Pilot Study With a Retinal Implant SystemA Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaA Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaAutologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaStudy of SAR421869 in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BObservational Study of the Argus® II Retinal Prosthesis SystemGanciclovir Implant Study for Cytomegalovirus RetinitisRandomized Trial for Retinitis PigmentosaStem Cells Therapy in Degenerative Diseases of the RetinaRandomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaNatural History and Genetic Studies of Usher SyndromeSafety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis PigmentosaThe FIGHT-RP1 StudyFeasibility and Safety of Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis PigmentosaRetinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaOral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind PatientsRepeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)Argus® II Retinal Prosthesis System Post-Market Surveillance StudyAutosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / GenesTrial of Oral Valproic Acid for Retinitis PigmentosaRETINA IMPLANT Alpha AMS in Blind Patients With Retinitis PigmentosaDevelopment of Visual Function Evaluation Method (2)Experimental and Clinical Studies of Retinal StimulationTreatment of RP and LCA by Primary RPE TransplantationStudy of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis PigmentosaArgus II Retinal Prosthesis System - Better Vision RP StudyStudy of a Suprachoroidal Retinal ProsthesisPhase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus RetinitisSafety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B GeneRod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)Clinical and Genetic Testing of Patients With Usher SyndromeSafety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsClinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis PigmentosaRepository for Inherited Eye DiseasesRetinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome MeasuresProspective Open Clinical and Genetic Study of Patients With Retinitis PigmentosaTranscorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study
P1050
Current approach in the diagnosis and management of posterior uveitisPerfluorocarbon liquid: its application in vitreoretinal surgery and related ocular inflammation.SOCS and Herpesviruses, With Emphasis on Cytomegalovirus RetinitisOptical coherence tomography angiography features of retinitis post-rickettsial feverhCMV-Mediated Immune Escape Mechanisms Favor Pathogen Growth and Disturb the Immune Privilege of the EyePharmacokinetics of Understudied Drugs Administered to Children Per Standard of CareSafety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind PatientsExercise and RP (AVAMC and Emory)The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus RetinitisThe Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSA Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSA Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSA Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) RetinitisA Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With GanciclovirThe Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSAn Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in ChildrenA Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDSA Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir TherapyAn Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDSAn Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous AccessA Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus RetinitisA Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV RetinitisAn Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS PatientsA Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDSOpen Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised PatientA Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisA Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDSThe Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVThe Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDSThe Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDSA Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With GanciclovirHPMPC (Cidofovir) Peripheral CMV Retinitis Trial ProtocolCMV Retinitis Retreatment TrialFoscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeA Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV RetinitisA Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use GanciclovirSuppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDSA Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment FailureA Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
P921
Q61862261-9C0CF324-F9D1-4663-93D0-F40A95E140E8Q61921373-D838D730-0719-40FD-9AB6-C664E790591AQ61924249-2392BDAC-D4C4-4CE2-A68D-1AC9C8306B3AQ61924250-637F1A1D-9E28-4C29-A4AB-CC3782530720Q61939028-30DC5AC7-1BC2-48AD-8600-27763370534BQ61957176-38F30402-AD8A-404D-8340-5454F565B425Q61969399-4DAC2D42-23C5-45CE-9D17-3F2DAE1BEC7EQ62030722-A9F243A6-A6CA-43AE-AF87-E46C8DE49C9DQ62030857-9112C7B1-733E-4486-821C-23F5ED4BEABBQ62031137-98E701EA-7DD3-4F1A-B302-90C71E71336AQ62031163-A2E7DAFB-A58B-4F8D-B8F2-67C279DDEBDAQ62105658-38DE8575-E017-44A7-A21A-FCF7C85C7E38Q63228846-FD71AC87-CA03-475C-8981-29376A86356EQ63229731-556E39DB-434C-479F-86F9-AC5FA127BC5FQ63316784-39553088-D6F7-4E86-9376-CAF69E6CD3CBQ63317003-61D04E63-61DD-444C-8D86-DF414A1CE063Q63317959-78663E7D-31D6-455E-815E-29B70E0C99BAQ63318801-F91A9D64-A453-4D16-984C-3C2180D13CD5Q63319978-437C1D0D-8555-4A70-B952-E86C2A608592Q63320709-560BD700-44C3-4ADA-9D3B-C3F91177EB84Q63340733-06C78715-9081-42BB-AF3A-5E5420AF9897Q63340902-18497197-37E2-4D25-8785-B832B2067374Q63393055-AAC137F8-C7FF-4D93-B51F-4DD80B89131BQ63393734-BC094758-0280-4E24-9BCF-E7E89FEE7DC9Q63394211-2C2142E2-A0D7-4609-A204-D8C1EDA83F95Q63398299-823B6E1E-0A9A-4767-A51E-A80BC0E030AAQ63402910-97299138-2DA0-41CF-A909-7C990EFAD735Q63404273-FD29483F-B91E-42CF-B3B1-CECFE181CC13Q63404404-21B27F19-E072-4BBD-8710-32B8B6F4E73EQ63405321-BFECFBBA-19D5-4B34-818A-45C06637A981Q63534109-427C8ECA-DD8B-4011-B112-68101D286545Q63534676-D41ABF27-219C-4A5D-8807-DCF0FB5D22D8Q63534995-44CF2BEA-A57E-4A63-AD9E-4A127D290F57Q63570686-C21F618B-FA35-4C37-BA22-911070C67321Q63571008-4738D134-DDC5-4599-A847-D7D2018C57F8Q63572443-DC914B2F-4DF6-47FE-BF7D-92EFDC5D1235Q63577227-5D55F214-DF2D-42FD-919A-B176A78D6D48Q63578287-45776233-E494-45F5-B01B-2E910F718197Q63578509-791DE507-42A4-4479-95E2-6165EE5C5D13Q63578712-2C426D93-0F9E-4A48-BACA-A89C4C71E251
P1050
Q30482534-A306343D-6247-4BA0-8129-C8D91CE0E47AQ37700513-D927911F-3E91-4DFE-816E-8BDC52906559Q64054763-08E94DF3-1435-4D47-AD32-D33759B7DF02Q64246229-443B71D2-250C-44EE-BC4A-CB71672B82B0Q64260529-34A856C6-F2D3-47B8-B60F-EA795DBAE455Q64648287-65A31147-E32A-4580-AB18-1CBB6E8BCF97Q64683960-E999F3C8-DF96-4814-8A37-71EBD1C67090Q64805615-85E3403E-3247-4CF8-AD0F-5FC77278FC53Q65472923-915F0F21-EBB6-4973-A2AF-36B119866D8DQ66040123-D2679A97-B8CA-4D6C-9FFD-63F5F072908FQ66040130-0B450FC6-E58B-42E5-8679-E53D020572C2Q66040234-746FE2D1-C814-4396-B290-FB88258C4A3CQ66040243-21FCCEE0-E3F4-45FA-BAC9-76E04D255850Q66040262-A38E06D6-E491-4608-B72C-7D626121FC74Q66040264-350F9C43-236C-412C-82B7-0360DB600022Q66040307-3A53B5A4-CA98-4614-A6B8-6B7F43126DEBQ66040308-27FE499B-1C36-4218-95CB-C38C5A85F530Q66040318-11999431-0575-4F2D-8818-C31EA9146CD8Q66040424-E9E15770-62DA-4A96-89F1-A56481619701Q66040431-833BAA77-78E2-48C5-8BBD-03BE0F382E61Q66040432-7621A941-FCEE-4DA6-8BBD-D2D7E10EA14DQ66040440-C2BBDD06-F3FC-423C-B5C1-394C0CF37D88Q66040495-9C10E823-4AE7-4EA0-AEFB-EEF7225C21B6Q66040527-57A9C36C-38C2-42D0-899E-DDE6E5DE3F40Q66040532-B4F8652B-463D-41D7-8BAC-A443C8BB8433Q66040541-85F83815-5D54-46F2-89E0-A8D3B5D7EDE1Q66040550-DC36BDA1-BDF2-422A-A539-57D7999D4C3BQ66040567-A85AB4AE-8D95-4ABA-BF3D-302B7EE7F4E3Q66040678-8F71E1C8-BE83-42E8-8818-160222E5595CQ66040724-2AB5125C-0F57-4AA8-9E6D-5DA317A171CFQ66040732-580A5CDB-30F8-4B01-88C8-813A6BAD7364Q66040744-FF3467E4-FC10-4653-8959-85EC3574B578Q66040920-B1BD1457-447E-4D73-BCC8-9ECC372E59CAQ66040952-571337EF-BEE1-453C-9E68-563988936EDCQ66040992-30FA895A-EDF3-4384-B1D7-A42553E6B4C1Q66041020-5D7229CF-4E33-4CEE-BD80-C833677031DBQ66041021-D11E080E-B872-495B-80FD-784EA763BFD5Q66041025-A442C014-6381-4EDE-A4A5-6517B75D8DD2Q66041027-79914632-8D4C-438F-936E-03BE07BCDEBAQ66041030-A8132EEE-B4E8-43AD-A62E-067CF851B8FF
P921
description
Human disease
@en
Krankheit
@de
inflammation de la rétine
@fr
qualunque infiammazione che interessa la retina
@it
مرض يصيب الإنسان
@ar
name
Retinitis
@de
Retinitis
@id
Retinitis
@nl
retinite
@it
retinite
@pt
retinitis
@ca
retinitis
@en
retinitis
@es
retinito
@eo
retinitt
@nn
type
label
Retinitis
@de
Retinitis
@id
Retinitis
@nl
retinite
@it
retinite
@pt
retinitis
@ca
retinitis
@en
retinitis
@es
retinito
@eo
retinitt
@nn
altLabel
Netzhautentzündung
@de
Retiniti
@it
netthinnebetennelse
@nn
التهاب الشبكية
@ar
prefLabel
Retinitis
@de
Retinitis
@id
Retinitis
@nl
retinite
@it
retinite
@pt
retinitis
@ca
retinitis
@en
retinitis
@es
retinito
@eo
retinitt
@nn
P2581
P486
P5806
P6366
P646
P672
P1296
P1748
P1889
P1995
P2581
P279
P2892
P31
P3417
P3827
P4229
P486
P493
P5082
P5806
P6366
2777016524
2908690212